FN1 and neoplasm: There have been a variety of early phase clinical trials with MMP inhibitors (Rudek et al., 2001; Winer et al., 2018), tumor-targeting immunocytokines (Johannsen et al., 2010), and fibronectin-targeting agents (Eigentler et al., 2011; Rudman et al., 2011; Danielli et al., 2015), in skin cancers which are comprehensively summarized in Table 1.